Skip to Content
MilliporeSigma
All Photos(1)

Key Documents

G0525000

Gonadorelin

European Pharmacopoeia (EP) Reference Standard

Sign Into View Organizational & Contract Pricing

Select a Size

5 MG
$236.00

$236.00

Check Cart for Availability
Request a Bulk Order
All Photos(1)

Select a Size

Change View
5 MG
$236.00

About This Item

Empirical Formula (Hill Notation):
C55H75N17O13
CAS Number:
33515-09-2
Molecular Weight:
1182.29
MDL number:
MFCD00167538
UNSPSC Code:
41116107
NACRES:
NA.24

$236.00

Check Cart for Availability
Request a Bulk Order

grade

pharmaceutical primary standard

API family

gonadorelin

manufacturer/tradename

EDQM

application(s)

pharmaceutical (small molecule)

format

neat

storage temp.

−20°C

SMILES string

[nH]1cnc(c1)CC(NC(=O)C6NC(=O)CC6)C(=O)NC(Cc4c5c([nH]c4)cccc5)C(=O)NC(CO)C(=O)NC(Cc3ccc(cc3)O)C(=O)NCC(=O)NC(CC(C)C)C(=O)NC(CCCNC(=N)N)C(=O)N2C(CCC2)C(=O)NCC(=O)N.OC(=O)C.O

InChI

1S/C55H75N17O13.C2H4O2.H2O/c1-29(2)19-38(49(80)67-37(9-5-17-60-55(57)58)54(85)72-18-6-10-43(72)53(84)62-25-44(56)75)66-46(77)26-63-47(78)39(20-30-11-13-33(74)14-12-30)68-52(83)42(27-73)71-50(81)40(21-31-23-61-35-8-4-3-7-34(31)35)69-51(82)41(22-32-24-59-28-64-32)70-48(79)36-15-16-45(76)65-36;1-2(3)4;/h3-4,7-8,11-14,23-24,28-29,36-43,61,73-74H,5-6,9-10,15-22,25-27H2,1-2H3,(H2,56,75)(H,59,64)(H,62,84)(H,63,78)(H,65,76)(H,66,77)(H,67,80)(H,68,83)(H,69,82)(H,70,79)(H,71,81)(H4,57,58,60);1H3,(H,3,4);1H2

InChI key

OOBWZCWPKJOGPF-UHFFFAOYSA-N

Looking for similar products? Visit Product Comparison Guide

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.
For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Gonadorelin EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Packaging

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Other Notes

Sales restrictions may apply.

Storage Class

11 - Combustible Solids

wgk_germany

WGK 3

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documents section.

If you need assistance, please contact Customer Support.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Ryo Okazaki
Clinical calcium, 24(3), 357-365 (2014-03-01)
Many drugs influence fracture risk besides glucocorticoid, a most common cause of drug-induced osteoporosis. It is well established that drugs used for anti-sex steroids therapy for breast and prostate cancers increase fracture risk, including GnRH agonists, aromatase inhibitors, and anti-androgens.
N E Kushlinskii et al.
Klinicheskaia laboratornaia diagnostika, (10)(10), 58-60 (2014-03-20)
Bone neoplasms - are a rare group of diseases, which ethiology and pathogenesis are not fully understood. We have studied 6 single nucleotide polymorphisms rs792/(GHI), rs7956547(IGFI), rs3761243(GNRH2), rs11737764(FGF2), rs6599400(FGFR3), and rs1690916(MDM2) associations with bone tumors. In our work we've detected
Matthis Synofzik et al.
Brain : a journal of neurology, 137(Pt 1), 69-77 (2013-12-21)
Boucher-Neuhäuser and Gordon Holmes syndromes are clinical syndromes defined by early-onset ataxia and hypogonadism plus chorioretinal dystrophy (Boucher-Neuhäuser syndrome) or brisk reflexes (Gordon Holmes syndrome). Here we uncover the genetic basis of these two syndromes, demonstrating that both clinically distinct
Grace C Dougan et al.
The Journal of pediatrics, 164(3), 655-657 (2013-12-26)
A male infant was diagnosed with partial androgen insensitivity caused by a novel mutation in the androgen receptor. At 3.5 months of age, he received 100 mg of testosterone intramuscularly over the course of 3 months to increase phallic size.
Jack M Zuckerman et al.
Urology, 83(3), 670-674 (2013-12-24)
To evaluate for a possible testosterone surge during transition of therapy from degarelix to leuprolide. We conducted an investigator-initiated, prospective, single-arm, open-label trial for evaluation of a potential testosterone surge during a transition of therapy from degarelix to leuprolide. Study
View All Related Papers

Questions

Reviews

No rating value

Active Filters

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service